Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmaceutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral Janssen-Cilag) in Patients With Tinea Pedis

Next Previous
X
Search
Trial Profile

Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmaceutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral Janssen-Cilag) in Patients With Tinea Pedis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapaconazole (Primary)
  • Indications Tinea pedis
  • Focus Registrational; Therapeutic Use
  • Sponsors Biolab Sanus Farmaceutica

    • Most Recent Events

    • 31 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 05 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top